HighlightsAgreement builds on existing Chiesi-Bespak collaboration, reinforcing a trusted relationship as Chiesi works to ...
Aptar Pharma and COVIRIX Medical collaborate to assess feasibility of adapting Aptar Pharma’s proprietary DPI platform for antiviral delivery.
UTHR shares jump 32% in six months as Tyvaso sales surge, earnings grow and Phase III TETON-2 data open a potential new market in IPF.
MannKind’s fair value estimate has been trimmed from US$9.61 to US$7.50, a roughly 22% cut that sets a more conservative anchor for the stock. This reset lines up with a split analyst backdrop, where ...
Aptar Pharma is starting a technical collaboration with COVIRIX Medical, a feasibility study for a dry powder inhalation (DPI ...
United Therapeutics Corporation (NASDAQ:UTHR) shares rose 9% Monday following the company’s announcement of a new $2 billion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results